Regular Article
Expression of Matrix Metalloproteinases and their Inhibitors in Experimental Retinal Ischemia-Reperfusion Injury in Rats

https://doi.org/10.1006/exer.2001.1152Get rights and content

Abstract

Matrix metalloproteinases (MMPs) are endopeptidases that degrade the extracellular matrix (ECM) and are involved in the pathogenesis of retinal degeneration along with tissue inhibitors of metalloproteinases (TIMPs). The present study examined the expression and activation of two specific members of MMPs (MMP-2 and MMP-9) and their related inhibitors (TIMP-1 and TIMP-2) in an experimental retinal ischemia-reperfusion injury. Retinal ischemia-reperfusion injury (RIRI) was induced in adult rats with a ligation method. After one hour of ischemia and a varied reperfusion time (0, 3, 6, 12, 24, 48 and 76 hr), the rat eyes were enucleated. Retinal extracts underwent zymographic analysis to measure the activity of MMP-2/9. The activity of TIMP-1 and TIMP-2 was measured by reverse zymography. The protein level was examined by Western blot. Immunohistochemistry analysis was undertaken to assess the anatomical distribution of MMP-9 in the retina after RIRI. The gelatinolytic activity of ProMMP-2 (72 kDa) was increased markedly at 6 hr after RIRI. ProMMP-9 (92 kDa) was not detected in the control specimens, while it appeared at 3 hr, increased markedly at 6 hr, and reached maximal levels at 24 hr after RIRI. The gelatinolytic activity found ian retinal extracts was shown to be inhibited by 10 m M EDTA and activated in vitro by a known metalloproteinase activator (4-aminophenylmercuric acetate (APMA)), indicating that these enzymes were of the metalloproteinase class. By western blot, MMP-2/9 levels increased parallel to protein activity level in zymography. No corresponding increase in TIMP-1 and TIMP-2 protein activity and protein level was detected by reverse zymography and western blot. Elevated levels of MMP-9 and its distribution in retina were confirmed by immunohistochemistry. Expression of MMP-9 was detected in the inner and outer segments of rat retina, and the level becomes stronger at 24 hr after RIRI. In this study, ProMMP-2 and ProMMP-9 were expressed and increased significantly, but their inhibitors (TIMP-1 and TIMP-2) remained relatively unaltered in ischemic retina after RIRI in rats. These results suggest that MMP-2 and MMP-9 may play an important role in the pathomechanism of retinal ischemic injury.

References (29)

  • C.A. Wilson et al.

    Blood-retinal barrier breakdown following experimental retinal ischemia and reperfusion

    Exp. Eye Res.

    (1995)
  • A. Das et al.

    Retina neovascularization is suppressed with a matrix metalloproteinase inhibitor

    Arch. Ophthalmol.

    (1999)
  • Z.S. Galis et al.

    Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue

    FASEB J.

    (1995)
  • Y. Gasche et al.

    Early appearance of activated matrix metoprotinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier disfunction

    J. Cereb. Blood Flow Metab.

    (1999)
  • Cited by (51)

    • Involvement of matrix metalloproteinases in capillary degeneration following NMDA-induced neurotoxicity in the neonatal rat retina

      2019, Experimental Eye Research
      Citation Excerpt :

      Activation of MMPs is a common characteristic of many diseases, including neurodegenerative disorders such as glaucoma (Guo et al., 2005; De Groef et al., 2014; Zalewska et al., 2016). In rodent models of retinal degeneration, increased expression and activity of MMP-9 in the retina promote death of RGCs (Chintala et al., 2002; Zhang et al., 2002, 2004; Zhang and Chintala, 2004; Guo et al., 2005; Mali et al., 2005; Manabe et al., 2005; Mathalone et al., 2007). MMP-9 degrades laminin and changes the structure of ECM, thus contributing to neuronal degeneration by a form of apoptosis known as anoikis (Chintala et al., 2002; Zhang et al., 2004).

    • A role of PSA-NCAM in the survival of retinal ganglion cells (RGCs) after kainic acid damage

      2019, NeuroToxicology
      Citation Excerpt :

      MMPs belong to the zinc proteases superfamily and specialize in degrading the extracellular matrix, cytokines, growth factors, cell surface receptors, and cell adhesion molecules (Bonnans et al., 2014; Rodriguez et al., 2010). MMPs show low expression and activity in normal conditions but are increased during remodelling or repair and in disease, such as diabetic retinopathy (Kowluru et al., 2014), glaucoma (De Groef et al., 2014), retina ischemia (Zhang et al., 2002). Activated astroglia and Müller cells are the major sources of MMP-9 protein (Zhang et al., 2004b).

    • Role of diagnostic factors associated with antioxidative status and expression of matrix metalloproteinases (MMPs) in patients with cancer therapy induced ocular disorders

      2018, Saudi Journal of Biological Sciences
      Citation Excerpt :

      and downregulated levels of TIMP1 and TIMP2 were detected in both cancer and cataract patients (Määttä et al., 2006). It has been demonstrated that the higher quantity of MMP-9 was examined in both posterior and anterior segments of eye after experimentally induced retinal reperfusion injury but the levels of TIMP 1 and 2 remained unchanged (Zhang et al., 2002). Thus, use of TIMP 1 & 2 or MMP-9 inhibitors can prevent corneal injuries.

    • MMP-9 inhibition facilitates amacrine cell loss after ouabain-induced retinal damage

      2015, Experimental Eye Research
      Citation Excerpt :

      The pathological activation of MMPs, in particular MMP-9, has been associated with neuronal degeneration and brain damage in ischemic stroke (Gu et al., 2002, 2005; Lee et al., 2004), traumatic brain injury (TBI) (Hadass et al., 2013; Zhang et al., 2010) and intracerebral hemorrhage (ICH) (Grossetete and Rosenberg, 2008; Tang et al., 2004; Xue et al., 2006). Retinal ischemia caused by optic nerve ligation (Chintala, 2002; Zhang et al., 2002; Zhang and Chintala, 2004; Zhang et al., 2004a), the elevation of intraocular pressure (Guo et al., 2005; Mathalone et al., 2007) and application of membrane-depolarizing potassium chloride (KCL) (Mali et al., 2005), excitotoxic NMDA (Manabe et al., 2005) and KA (Zhang et al., 2004b) has been shown to increase MMP-9 expression and activation in rats or mice. Synthetic inhibitors of MMPs or a deficiency in MMP-9 in the retinas have been shown to protect against RGCs loss and the reduction of laminin in the inner limiting membrane of the retina, suggesting that MMP-9 promotes the death of RGCs by degrading the laminin and changing the ECM (Chintala, 2002; Mali et al., 2005; Manabe et al., 2005; Zhang et al., 2004b).

    • Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: Correlations with extent, duration of RRD and PVR grade

      2014, Cytokine
      Citation Excerpt :

      The diverse MMP functionality is apparent during RRD. Collagenases (such as MMP-1) and stromelysins have been reported to be expressed at the onset of RRD and are associated with increased matrix degradation [23]. Increased MMP-9 activity has been associated with acute pathological circumstances and also appears to be implicated in PVR pathophysiology [18].

    View all citing articles on Scopus
    f1

    Address correspondence to: Taiji Sakamoto, Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. E-mail: [email protected]

    View full text